hepatocarcinoma-intestine-pancreas protein, human
Biologicalexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01318525)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Regenerating islet-derived protein 3-alphaSupplementation
supplementation - HIP/PAP
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alf-5755
- alf-5755
- hepatocarcinoma-intestine-pancreas protein, human
- hip-pap protein, human
- ingap protein, human
- ingap protein, rat
- islet neogenesis-associated protein, human
- pancreatitis-associated protein
- pancreatitis-associated protein 2, rat
- pancreatitis-associated protein 3, rat
- pancreatitis-associated protein, human
- pancreatitis-associated protein i, human
- pancreatitis-associated protein iii, rat
- pancreatitis-associated protein ii, rat
- pancreatitis-associated protein i, rat
- pancreatitis-associated protein, rat
- pap1 protein, human
- pap1 protein, rat
- pap2 protein, rat
- pap3 protein, rat
- pap-h protein, human
- papiii protein, rat
- reg-2 protein, rat
- reg3a protein, human
- reg3a protein, mouse
- reg3b protein, rat
- reg3g protein, rat
- regenerating islet-derived 3alpha protein, human
- regenerating islet-derived 3 alpha protein, mouse
- regenerating islet-derived 3 beta protein, rat
- regenerating islet-derived 3 gamma protein, rat
- regenerating islet-derived protein 3
- regeneration gene protein 2, rat
- regiii-alpha protein, mouse
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01318525 | Phase 2 | Oct 1, 2010 | Alfact Innovation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alfact Innovation | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1